{"id":9319,"date":"2025-06-02T12:07:05","date_gmt":"2025-06-02T12:07:05","guid":{"rendered":"https:\/\/ipp-news.com\/?p=9319"},"modified":"2025-06-02T12:07:05","modified_gmt":"2025-06-02T12:07:05","slug":"sanofi-makes-biggest-european-pharma-deal-of-2025-with-blueprint-purchase","status":"publish","type":"post","link":"https:\/\/ipp-news.com\/?p=9319","title":{"rendered":"Sanofi makes biggest European pharma deal of 2025 with Blueprint purchase"},"content":{"rendered":"
In a major move underscoring its ambition to lead in rare diseases and immunology, French pharmaceutical giant Sanofi announced its plan to acquire US-based Blueprint Medicines for up to $9.5 billion.<\/p>\n

The deal was announced by a press release on Sanofi’s website.\u00a0It is the largest by a European healthcare company this year and will see Sanofi paying $129 per share in cash, a significant premium that sent Blueprint\u2019s stock soaring in premarket trading.<\/p>\n

Blueprint Medicines, known for its specialty in treating systemic mastocytosis a rare blood disorder marked by the overproduction of mast cells brings to Sanofi a strong foothold in a niche yet critical area of medicine.<\/p>\n

The acquisition adds the FDA-approved drug Ayvakit, the only treatment for advanced systemic mastocytosis, to Sanofi\u2019s growing immunology portfolio.<\/p>\n

Sanofi CEO Paul Hudson framed the deal as a strategic leap forward, enhancing the company\u2019s pipeline and reinforcing its transformation into a global leader in immunology.<\/p>\n

We announced an agreement to acquire Blueprint Medicines, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases.
\n\u2014 Sanofi (@sanofi) June 2, 2025<\/p>\n

With a promising pipeline including next-generation therapies like elenestinib and BLU-808, the acquisition fits into Sanofi\u2019s broader ambition of innovation despite recent setbacks, including a failed lung disease drug trial.<\/p>\n

Industry analysts from JP Morgan praised the acquisition for its strategic and financial merits, forecasting Ayvakit could generate $2 billion in annual sales by 2030.<\/p>\n

Sanofi\u2019s ongoing spree of acquisitions, including Vigil Neuroscience and Inhibrx, signals a company doubling down on R&D investments to reshape its future.<\/p>\n

The acquisition aligns with Sanofi\u2019s broader strategy to invest heavily in US\u00a0manufacturing and research, tapping into incentives and momentum driven by recent government policies.<\/p>\n

With Blueprint Medicines now joining its portfolio, Sanofi cements its stake in cutting-edge immunology treatments and rare disease therapies, positioning itself for long-term growth in a competitive pharmaceutical landscape.<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

In a major move underscoring its ambition to lead in rare diseases and immunology, French pharmaceutical giant Sanofi announced its plan to acquire US-based Blueprint Medicines for up to $9.5 billion. The deal was announced by a press release on Sanofi’s website.\u00a0It is the largest by a European healthcare company this year and will see […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-9319","post","type-post","status-publish","format-standard","hentry","category-english-news"],"_links":{"self":[{"href":"https:\/\/ipp-news.com\/index.php?rest_route=\/wp\/v2\/posts\/9319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipp-news.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipp-news.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipp-news.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ipp-news.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9319"}],"version-history":[{"count":0,"href":"https:\/\/ipp-news.com\/index.php?rest_route=\/wp\/v2\/posts\/9319\/revisions"}],"wp:attachment":[{"href":"https:\/\/ipp-news.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipp-news.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipp-news.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}